Preclinical models at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

23 organizations at ENA 2026 present work in preclinical and animal models and drug screening, led by CROs and suppliers. Between them they bring 61 presentations to the program. Most represented: Vall d'Hebron Institute of Oncology (VHIO), Crown Bioscience and Biocytogen. As of Oct 13, 2026.

All 254 organizations at ENA 2026 →

Showing 1–8 of 23 organizations

Organization	ENA 2026 Attendance
Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain
vhio.net Cancer centres & hospitals Barcelona cancer research institute at Vall d'Hebron University Hospital, combining translational research with an early-phase clinical trials unit.	Session Wed Nov 18 1:30–1:35pm Opening Ceremony: Welcome and opening of the ENA 2026 Symposium Session Wed Nov 18 1:35–2:20pm Keynote Lecture: The rise of biotech in APAC Session Wed Nov 18 2:20–3:50pm Plenary Session 1: The next wave of immune engagers in cancer therapy: beyond CD3 and beyond T cells Immuno-oncology Talk Thu Nov 19 3:20–3:40pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Targeting YAP/TEAD as monotherapy and in rational combinations Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Phase Ib study of OMO-103 in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma Targeted agents Session Fri Nov 20 8–9:30am Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Cell therapy Talk Fri Nov 20 8:40–9am Part of Plenary Session 5: Next-generation cell therapies (CAR-T, TCR) Neoantigen TCR-T Cell therapy Talk Fri Nov 20 9:45–10am Part of Workshop 7: Novel Methodologies & Endpoints in New Drug Development Multi-omics including Spatial Transcriptomics Early clinical Talk Fri Nov 20 12–12:10pm Part of Plenary Session 6: Proffered papers MYC Inhibition with OMO-103 Restores TNF-Superfamily Signaling and Uncovers Actionable Immunotherapy Vulnerabilities in KRAS-Mutant NSCLC Targeted agents · Immuno-oncology Session Fri Nov 20 3–4:50pm Plenary Session 7: Proffered papers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Novel clinical trial design Digital Remote Patient Monitoring in Early-Phase Oncology Clinical Trials: A Prospective Pilot Study of Feasibility and Implementation Early clinical Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models A preclinical patient-derived xenograft platform to model resistance to cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in oestrogen receptor-positive breast cancer. Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Integrative molecular profiling of a breast cancer (BC) patient-derived xenograft (PDX) platform for biomarker discovery Preclinical models
Crown Bioscience San Diego, CA
crownbio.com CROs & CDMOsExhibitor Preclinical oncology CRO offering patient-derived xenograft, organoid and syngeneic models plus translational and biomarker services.	Booth Exhibiting at Booth 30 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Developing Different Preclinical RAS Inhibitor Resistant Xenograft Models for Next-Generation Therapeutic Evaluation Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Integrated Organoid Screening Approaches Enable Preclinical Assessment of Targeted Protein Degrader Efficacy and Target Engagement Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Animal Models Characterization of a Panel of PDX Models Derived from c-MET Targeting ADCs Pretreated Colorectal Cancer Patients for Therapeutic Evaluation Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Animal Models Establishing Preclinical Mouse Models for Translational Cancer Cachexia Research Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models End-to-end in vitro and in vivo evaluation of radiopharmaceuticals in patient-derived models Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Benchmarking Multiple Comparison Procedures for Patient-Derived Xenograft Tumor-Volume Studies: Toward Statistically Justified and Ethically Grounded Study Design Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models PDX-Derived Organoids Demonstrate High Concordance with In Vivo Responses Across KRAS Inhibitors and Antibody-Drug Conjugates Preclinical models
Biocytogen Beijing, China
biocytogen.com CROs & CDMOsExhibitor Provides humanized mouse models, preclinical pharmacology and antibody discovery, and develops its own antibody and ADC candidates.	Booth Exhibiting at Booth 23 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors ADCs & radioligands Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology BCG024: A Novel DLL3×CD3×4-1BB Trispecific T Cell Engager Enhances T Cell Persistence and Functionality in Preclinical Models Immuno-oncology Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Animal Models The B-hCRBN Mice Model Facilitates PROTACs Studies Based on CRBN Ligands Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Animal Models Utilizing a Humanized CD8 Mouse Model for Non-clinical Studies of Cancer Immunotherapy Preclinical models
Masaryk University Brno, Czech Republic
muni.cz Universities & institutes Public research university in Brno, Czech Republic, with faculties of medicine and science.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Profound changes of the p53 network induction on the translatome and proteome levels determine cellular response to MDM2 inhibition Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Optimizing p53/ISR-based cancer therapy through real-time in vivo monitoring of p53 activation Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Stiffness, stress, and stroma: patient-specific 3D spheroid models reveal biomechanical and cellular determinants of pancreatic cancer progression Preclinical models
Institute of Oncology Research (IOR) Bellinzona, Switzerland
ior.usi.ch Universities & institutes Cancer research institute affiliated with Università della Svizzera italiana, with programmes including lymphoma and prostate cancer.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Screening High-throughput synergy screening of blood-brain-barrier penetrant compounds identifies druggable targets that potentiate BTK inhibition in CNS lymphomas Preclinical models Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Transcriptional and epigenetic inducers of proximity as antitumor agents in marginal zone lymphomas Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents First characterization of the synthetic peptide CIGB-552 in B-cell lymphomas demonstrates antitumor activity in drug-resistant models and enhancement of BTK-targeted therapies Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents The CBP/EP300 inhibitor TT125-802 shows antitumor activity in marginal zone lymphoma models and can improve the effects of BTK inhibitors Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology FF01, a novel heavy chain antibody targeting the human endogenous retrovirus envelope, displays anti-lymphoma activity Immuno-oncology Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs BTK and BCL2 targeting with orelabrutinib (ICP-022) and mesutoclax (ICP-248): single-agent and combination activity in marginal zone lymphoma, including drug-resistant derivatives Drug design Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Natural extracts show anti-proliferative activity in lymphoma cells with resistance to targeted agents Drug design
Evotec Hamburg, Germany
evotec.com CROs & CDMOs Drug discovery and development partner offering integrated research services from target identification to preclinical studies.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Screening 3D patient-derived cancer models for target validation and drug discovery Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Tumour immunology and inflammation Quantifying Immunological Synapse to Optimize Immune Cell Engagers and Cancer Immunotherapies Immuno-oncology
Immuneering Cambridge, Massachusetts
immuneering.com Biotech Clinical-stage oncology company developing atebimetinib, a deep cyclic MEK inhibitor for MAPK-driven cancers.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Atebimetinib, a deep cyclic inhibitor of MEK, combined with chemotherapy: preclinical rationale for treatment of anaplastic thyroid cancer (ATC) Biomarkers Talk Thu Nov 19 2:20–2:25pm Part of Posters in the Spotlight, session 1 Patient-aligned 3D tumor models identify biomarker-enriched atebimetinib (IMM-1-104) combination strategies in pancreatic ductal adenocarcinoma Preclinical models · Targeted agents
University of Helsinki Helsinki, Finland
helsinki.fi Universities & institutes Public research university in Finland with a faculty of medicine and cancer research programmes.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Screening Predictive MYC synthetic lethal screening reveals uncharacterized polo-like kinase 1 vulnerability in MYC high triple-negative breast cancer cells Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Bone-Derived Extracellular Matrices Modulate Osteosarcoma Drug Response and Invasive Phenotypes Preclinical models